Last reviewed · How we verify
JT001
JT001 is a small molecule that targets the SGLT2 receptor.
JT001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | JT001 |
|---|---|
| Also known as | VV116, VV116 placebo, DeuremidevirHydrobromideTablets |
| Sponsor | Shanghai Vinnerna Biosciences Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, JT001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- The Mass Balance Study of [14C]JT001 (PHASE1)
- A Real-World Study of JT001 for COVID-19
- To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 (PHASE1)
- A Study in Elderly Chinese Subjects With Underlying Diseases (PHASE1)
- A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function (PHASE1)
- A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (PHASE1)
- JT001 (VV116) for the Early Treatment of COVID-19 (PHASE2, PHASE3)
- JT001 (VV116) for the Treatment of COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |